Windtree Therapeutics, a Nasdaq-listed biotech firm, announced plans to purchase up to $700 million worth of BNB, the fifth-largest cryptocurrency, following its recent all-time high. The company is raising approximately $520 million to fund these acquisitions after initially planning to buy $200 million. Windtree has partnered with cryptocurrency exchange Kraken for asset custody. The funding will come from a $500 million equity line of credit with an unnamed institutional investor and a $20 million stock-purchase agreement with Build and Build Corp. CEO Jed Latkin emphasized the importance of securing funds for this strategy, especially as BNB continues to grow in prominence within the crypto market. With BNB currently having a market cap of $106.9 billion, Windtree joins a broader trend of public companies integrating cryptocurrency into their balance sheets. Other firms, like Nano Labs, have also recently announced significant BNB acquisitions, indicating a rising interest in digital assets among traditional companies.

Source đź”—